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Background: Several studies have shown a positive association between anxiety and 
obesity, particularly in women. We aimed to study whether sex hormone alterations 
related to obesity might play a role in this association.
Patients and methods: Data for this study were obtained from a population-based 
cohort study (the LIFE-Adult-Study). A total of 3,124 adult women (970 premenopausal 
and 2,154 postmenopausal) were included into the analyses. The anxiety symptomatology 
was assessed using the GAD-7 questionnaire (cut-off ≥ 10 points). Sex hormones were 
measured from fasting serum samples.
Results: We did not find significant differences in anxiety prevalence in premenopausal 
obese women compared with normal-weight controls (4.8% vs. 5.5%). Both obesity 
and anxiety symptomatology were separately associated with the same sex hormone 
alteration in premenopausal women: higher total testosterone level (0.97 ± 0.50 in 
obese vs. 0.86 ± 0.49 nmol/L in normal-weight women, p = 0.026 and 1.04 ± 0.59 
in women with vs. 0.88 ± 0.49 nmol/L in women without anxiety symptomatology, p = 
0.023). However, women with anxiety symptomatology had non-significantly higher 
estradiol levels than women without anxiety symptomatology (548.0 ± 507.6 vs. 426.2 ± 
474.0 pmol/L), whereas obesity was associated with lower estradiol levels compared 
with those in normal-weight group (332.7 ± 386.5 vs. 470.8 ± 616.0 pmol/L). Women 
with anxiety symptomatology had also significantly higher testosterone and estradiol 
Abbreviations: GABAA, Gamma-Aminobutyric Acid A; BMI, body mass index.
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composition (p = 0.006). No associations of sex hormone levels and BMI with anxiety 
symptomatology in postmenopausal women were found.
Conclusions: Although both obesity and anxiety symptomatology were separately 
associated with higher testosterone level, there was an opposite impact of anxiety and 
obesity on estradiol levels in premenopausal women. We did not find an evidence that 
the sex hormone alterations related to obesity are playing a significant role in anxiety 
symptomatology in premenopausal women. This could be the explanation why we did 
not find an association between obesity and anxiety. In postmenopausal women, other 
mechanisms seem to work than in the premenopausal group.
Keywords: anxiety, body mass index, obesity, sex hormones, testosterone, estrogen, women
INTRODUCTION
Anxiety disorders affect 25% of the population in the Western 
world, which makes them the most frequent psychiatric condition 
these days (1). They are chronic and more prevalent in females 
than males and are typically complicated by coexistent mental 
and somatic disorders (2). Moreover, there are also differences 
in comorbidities, symptoms, and how these disorders affect each 
gender (3).
Differences in prevalence, as well as the fact that puberty, 
pregnancy, and menopause are important precipitants for onset, 
exacerbation, recurrence, and relapse of anxiety disorders, 
further indicate an important role of hormones, including and in 
particular sex hormones (2).
As for hormones, testosterone is reported to have a crucial 
influence on the course of anxiety disorders (4). Testosterone, 
often referred as a male hormone, is also present in women, 
although in about 10 times lower concentrations (5). It is 
hypothesized that its higher concentrations in males might be one 
of the reasons for the sex differences in prevalence of anxiety (4). 
The effects of testosterone are mediated through the stimulation 
of estrogen receptors, androgen receptors, or GABAA receptors 
in several brain regions, resulting in various biological outcomes 
(6). It has been reported in the literature that testosterone can 
relieve anxiety and depression while inducing subjective feeling 
of an improved mood in both genders (2).
Testosterone’s anxiolytic (7, 8) and anxiogenic (9, 10) effects 
have been studied in several animal studies as well. Various 
activational effects of testosterone on the anxiety-like behavior 
have been observed in adult male rodents. Gonadectomized 
adult male rodents showed increased anxiety-like behavior, and 
this effect could be reversed by testosterone replacement (11). 
Moreover, it was shown that testosterone replacement had the 
exact same anxiety-relieving effect as the administration of the 
typical tricyclic antidepressant in male rats (12). However, very 
inconsistent outcomes of studies investigating testosterone’s 
anxiolytic effect in female rodents have been published. Some 
studies provide supporting evidence for a beneficial role of 
testosterone in intact adult female rodents (13).
Women with anxiety disorders were previously proved to have 
decreased testosterone levels. When compared with healthy controls, 
women with social phobia, generalized anxiety, or agoraphobia 
produced lower levels of testosterone in their saliva (14).
On the other side, also an association between higher 
testosterone levels and anxiety has been shown in women with 
polycystic ovarian syndrome (state of hyperandrogenism) (15).
Contradictory results from preclinical and clinical research 
were published regarding the association of anxiety with estrogen 
levels as well (16, 17). Higher estrogen levels were significantly 
associated with anxiety and anxiety-like behaviors in some 
studies (18). The risk for developing of any anxiety disorder 
significantly increases at menarche, as the circulating estradiol 
abruptly increases from prepubertal to its adult levels during the 
stage of sexual development (19).
On the other hand, increased anxiety symptoms were also 
noticed in women after surgical or natural menopause (20) and 
close to the end of the luteal phase of the menstrual cycle (21) – 
periods characterized by decline in circulating estradiol levels. 
The most probable explanation is that the effect of estradiol on 
anxiety behavior is dose dependent and varies from anxiogenic 
(22) to null (23) to anxiolytic (24).
Several conditions might be associated with changes in 
sex hormone levels in women. The most prevalent is obesity, 
which might be associated with changes in hypothalamic–
hypopituitary–gonadal axis and also altered testosterone and 
estradiol levels (25). This is also due to the fact that fat tissue 
per se represents an intracrine source of sex hormones, and 
this was shown to be gender specific. Body mass index (BMI) 
is positively associated with testosterone levels in women, while 
there is an inverse association of BMI and estrogen (26). It has 
been reported that severity of obesity is directly linked with the 
amplitude of hormonal changes (27), which can be reversed by 
the reduction of weight (28).
A positive association between overweight and anxiety 
disorders has been shown in several studies (29, 30), although 
the underlying mechanisms of this association are still not 
completely understood. Alterations of testosterone levels (higher 
levels in women) associated with increased BMI might represent 
one of the possible risk factors in the etiopathogenesis of anxiety.
We hypothesized that all three factors – anxiety, BMI, and sex 
hormones – might be strongly interconnected. To the best of our 
knowledge, all three factors have not been studied together so far.
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In the present study, we (1) focused on associations between 
anxiety symptomatology and BMI, (31) focused on associations 
between anxiety symptomatology and sex hormones and to 
compare them with sex hormone alterations in obesity, and 
(2) studied the impact of both BMI and altered sex hormone 
levels on anxiety in one regression model.
PATIENTS AND METHODS
Study Population
Data presented in this study were obtained from the (LIFE)-
Adult-Study conducted by the Leipzig Research Centre for 
Civilization Diseases. This study included >10,000 participants 
selected randomly. The objective of the LIFE-Adult-Study is 
to investigate the prevalence, markers of early onset, genetic 
factors, and lifestyle determinants of major civilization diseases, 
including metabolic diseases and depression (32). The study was 
approved by the responsible institutional ethics committee of 
the Medical Faculty of the University of Leipzig (PV 2016-274-
04). All participants provided written informed consent. The 
data privacy and safety concept of the study were endorsed by a 
responsible data protection officer.
Medical History and Medications
A structured interview was performed in all participants of 
the study, where they were asked about 70 common medical 
diagnoses, which were previously confirmed by their physician. 
In women, data on menstrual cycle [number of days/months/
years since the last menstrual period (LMP)], history of bilateral 
oophorectomy and hysterectomy, and past or present use of 
contraception pills or hormonal replacement therapy were 
included. Data on all other medications taken within past 7 days 
before study day were gathered. Medications were identified by 
bar codes, following ATC classification.
Anthropometry
Trained study personnel measured the body weight and height 
according to standardized protocols. For measuring body 
weight, an electronic scale (SECA 701, Seca Gmbh & Co KG) 
with a precision of 0.01 kg was used; body height was assessed by 
means of a stadiometer (SECA 240) to the nearest 0.1 cm (32). 
Underweight was assessed as BMI < 18.5 kg/m2, normal weight 
as BMI ≥ 18.5 and < 25 kg/m2, overweight as BMI ≥ 25 kg/m2 
(pre-obesity BMI > 25 and 29.9 kg/m2 and obesity ≥ 30 kg/m2).
Hormonal Analyses
Blood samples were collected in all participants of the study 
between 7:30 and 10:30 a.m. after more than 10 hours of 
fasting). Analyses of levels of selected hormonal (sex hormone-
binding globulin and total testosterone) and biochemical 
(albumin) parameters (for calculation of free testosterone) were 
performed on fresh serum samples in a highly standardized 
manner (32). Biochemical analysis was performed by fully 
automated Cobas system (Roche, Mannheim). Intra-assay and 
inter-assay coefficients of variation were given exemplarily by 
100 subsequent analyses during the time of recruitment study of 
probands: results of sex hormone-binding globulin were <3.4% 
for the range between 25.4 and 54.2 nmol/L, results of estradiol 
were below 4.3% for the range between 387 and 2,052 pmol/L, 
and results of total testosterone were below 4.9% for the range 
between 3.73 and 19.07 nmol/L. Free testosterone was calculated 
using Vermeulen’s formula (33). Composition of estradiol 
and total testosterone or free testosterone was calculated by 
multiplying serum estradiol levels by total or free testosterone 
serum levels, respectively.
Assessing of Anxiety Symptomatology
We used a German version of the established self-report 
questionnaire Generalized Anxiety Disorder 7 (GAD-7) to 
screen the presence of anxiety symptomatology. The GAD-7 
questionnaire (covering symptoms of generalized anxiety 
disorder, panic disorder, social anxiety disorder, and post-
traumatic stress disorder) consists of seven items asking patients 
how often, during the last 4 weeks, they were bothered by each 
symptom. The answer options were “not at all,” “several days,” 
“more than half the days,” and “nearly every day” scored from 0 to 
3 points. A total score of ≥10 indicates the presence of an anxiety 
symptomatology (34).
Exclusion Criteria
We excluded all women 1) using medications possibly 
influencing either hormonal or mental status, including 1A) 
external hormones [ATC groups: G02, other gynecologicals (n = 
210); G03, sex hormones and genital modulators (n = 766); H02, 
systemic corticosteroids (n = 109); and L02, endocrine therapy 
(n = 60)], 1B) CNS or psychotropic drugs [N03, antiepileptics 
(n = 143); N04, antiparkinsonics (n = 61); N05, psycholeptics 
(n = 344); N06, psychoanaleptics (n = 516); and N07, other 
CNS drugs (n = 61)]; (31) individuals with hypothyreosis or 
hyperthyreosis (n = 11); 2) perimenopausal (6–12 months since 
LMP, n = 136) and postpartal (1 year after delivery, n = 28) 
women, as both periods are significantly related to increased 
onset and prevalence of anxiety disorders (35); 3) underweight 
individuals (n = 40) because of small numbers; 4) all individuals 
with severe renal/hepatal/neurologic disease or cancer in the 
last year (n = 276); and 5) individuals diagnosed or/and treated 
for depression (n = 462).
Classification Process
Women were classified according to age and LMP into 
premenopausal (0–6 months since LMP or <45 years) and 
postmenopausal (>12 months since LMP or ≥55 years or bilateral 
oophorectomy), in accordance with guidelines used by Breast 
Cancer Consortium (36).
Cohort Description
The study sample included 3,124 women of whom 970 (31.0%) 
were premenopausal (45.0 ± 6.6 years) and 2,154 (68.9%) were 
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postmenopausal (64.2 ± 8.0 years). In the group of premenopausal 
women, 53.7% were of normal-weight (mean BMI 22.1 ± 
1.6 kg/m2), 28.1% were pre-obese (mean BMI 27.1 ± 1.4 kg/m2), 
and 17.0% were obese (mean BMI 35.2 ± 5.0 kg/m2). In the group 
of postmenopausal women, 32.5% were normal weight (mean 
BMI 22.8 ± 1.6 kg/m2), 37.9% were pre-obese (mean BMI 27.4 ± 
1.4 kg/m2), and 29.0% were obese (mean BMI 34.2 ± 4.1 kg/m2).
Statistical Analyses
Values for the sample description are given as mean ± SD. 
Comparison between groups was tested using t-test for metric 
variables and by Fisher’s test or chi-square test for binary 
variables. Logistic regression analysis was performed using 
presence of anxiety symptomatology (GAD-7 ≥ 10 points) 
as a dependent variable, and BMI, testosterone, and age as 
independent variables. p values less than 0.05 were considered as 
statistically significant. Statistical analyses were performed with 
SPSSv25 software (IBM, NY, USA). Graphs were plotted with 
GraphPad Prism 7.04 (GraphPad Software, CA, USA).
RESULTS
Prevalence of Anxiety in Women
In all women included into the study, the prevalence of anxiety 
symptomatology was 5.0%, with no significant differences between 
the premenopausal and postmenopausal groups (Figure 1A).
Association Between Anxiety 
Symptomatology and BMI
We did not find any significant differences in the prevalence of 
anxiety symptomatology between normal weight, and obese 
premenopausal, postmenopausal women (Figure 1B).
Associations of Anxiety Symptomatology 
and BMI with Sex Hormones
Premenopausal women with anxiety symptomatology showed 
higher total testosterone levels than did women without anxiety 
symptomatology (1.04 ± 0.59 vs. 0.88 ± 0.49 nmol/L, p = 0.023) 
(Figure 2A). Free testosterone and estradiol levels were also 
higher in the women with presence of anxiety symptomatology; 
however, the differences were not significant (Figure 2B, C). 
Significant differences in anxious versus non-anxious women 
were observed in compositions of estradiol with total and free 
testosterone, respectively (Figure 2D, E).
In postmenopausal women, no significant association between 
anxiety symptomatology and testosterone (as well as with other 
sex hormones) was found (Figure 2A–E).
Premenopausal women with obesity showed higher total 
testosterone (0.97 ± 0.50 vs. 0.86 ± 0.49 pmol/L, p = 0.026) 
and free testosterone levels (12.8 ± 8.3 vs. 8.9 ± 6.2 pmol/L, 
p < 0.001) and lower estradiol levels (332.7 ± 386.5 vs. 470.8 ± 
516.0 pmol/L, p = 0.004) than did normal-weight women 
(Figure 2A–C).
Association Between Anxiety 
Symptomatology, BMI, and Sex Hormones
In the logistic regression analysis, anxiety symptomatology was 
significantly associated with total testosterone (∆R2 = 0.016, 
OR = 1.773, p = 0.025), but not BMI (Table 1).
In postmenopausal women, total testosterone, estradiol, and 
BMI were not associated with anxiety symptomatology (Table 1).
DISCUSSION
Both anxiety symptomatology and obesity were associated with 
higher testosterone levels but had opposite impact on the estradiol 
FIGURE 1 | Prevalence of anxiety. Displayed in % with 95% confidential 
intervals (calculated with the Wilson–Brown method). Significant differences 
are marked with * (p between 0.05 and 0.01), ** (p between 0.01 and 
0.001), and *** (p < 0.001). Abbreviations: PeM, premenopausal; PoM, 
postmenopausal.
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FIGURE 2 | Associations of anxiety symptomatology and obesity with testosterone and estradiol levels in premenopausal and postmenopausal women. (A) Total 
testosterone levels, (B) free testosterone levels, (C) estradiol levels, (D) composition of total testosterone with estradiol levels, and (E) composition of free 
testosterone with estradiol levels. Significant differences are marked with * (p between 0.05 and 0.01), ** (p between 0.01 and 0.001), and *** (p < 0.001). 
Abbreviations: NA, non-anxious (anxiety symptomatology not present = GAD-7 < 10 points); A, anxious (anxiety symptomatology present = GAD-7 ≥ 10 points); 
NW, normal weight (BMI between 18.5 and 25 kg/m2); O, obese (BMI ≥ 30 kg/m2).
Anxiety, BMI and Sex Hormones in WomenStanikova et al.
6 July 2019 | Volume 10 | Article 479Frontiers in Psychiatry | www.frontiersin.org
levels in premenopausal women. However, BMI was not associated 
with anxiety symptomatology. No significant associations between 
anxiety symptomatology and sex hormone levels were found in 
postmenopausal women.
Anxiety Symptomatology and 
Testosterone
The positive association between anxiety and testosterone levels 
in women, found in our study, has been observed in several 
others, particularly in studies of women with polycystic ovarian 
syndrome (state of hyperandrogenism) (37, 38). A similar 
association has also been found in animal studies. In a study by 
Goel and Bale (9), an anxiogenic effect after administration of 
testosterone in female mice was observed. Increased androgen 
levels in prenatal period were proved to be associated with 
anxiety-like behavior in rats. This effect was reversible by the 
administration of estrogen receptor modulators and androgen 
receptor blockers. This study also reported anxiety-like behavior 
in female rats after they were injected testosterone into the 
amygdala (39).
Females were proved to have more sensitive receptor 
binding testosterone despite about 10 times lower levels of 
testosterone than have males (2, 5). This can be seen also in our 
study—premenopausal women with anxiety symptomatology 
had higher total testosterone levels, but the mean levels were 
still within the reference range. This is implying that women 
might be sensitive not only to extreme but also to more subtle 
alterations of testosterone levels. The fact that this association 
was observed in premenopausal women only might be related 
to physiological changes of testosterone levels over a woman’s 
lifespan. Between 20 and 40 years, a steep decline of testosterone 
levels can be seen in women (40). Premenopausal women could 
be therefore more sensitive to the (pathophysiological) increase 
of testosterone level.
On the other hand, it is necessary to say that several studies 
have found an association between lower testosterone and 
anxiety (or some specific subtypes) in women (14, 41).
The most possible explanation is that the association 
between anxiety and testosterone levels might be not linear 
and that the effect is dose dependent. This was observed in 
one of the most cited animal study focused on the effect of 
testosterone on anxiety (42). Differences in the study design 
(e.g., with regard to the menopausal status of women) as 
well as studied samples might also play a role in the various 
outcomes.
Anxiety Symptomatology and BMI
Several large epidemiologic studies have found a positive 
relationship between anxiety disorders (or some specific 
subtypes) and overweight or obesity in women and men, i.e., 
increasing prevalence with increasing BMI (29). A moderate but 
positive relationship between overweight and anxiety disorders 
was also observed in large epidemiological studies and meta-
analyses (30, 43).
In our study, no significant association between BMI and 
prevalence of anxiety symptomatology regardless of gender or 
menopausal status in women was found.
There might be several possible explanations for these 
contradictory results. The first possibility is the way that anxiety 
was measured. Most of the published studies focused on the 
lifetime or on the 12-month prevalence of anxiety (29, 44), and 
only a few studies focused on current anxiety symptomatology 
with current BMI. In the study by Jorm et al. (45) investigating 
the association between current anxiety symptomatology and 
current BMI status, similar results to our study have been found. 
Anxiety symptomatology and BMI are largely time-dependent 
phenotypes; e.g., higher anxiety symptoms earlier in life may 
contribute to increased BMI later in life and vice versa. To the best 
of our knowledge, a study investigating the association between 
BMI in the age of the onset of anxiety disorder is missing.
Another possible explanation for these contradictory findings 
of above-mentioned studies and our study is that most of them 
did not use any exclusion criteria, which may have an impact 
on the results of anxiety and weight of an individual as well. In 
our study, by contrast, all individuals treated with psychotropic 
or selected CNS drugs, as well as with severe somatic conditions 
(e.g., cancer), were excluded. Also, comorbidity of depression 
and anxiety is high (29); it could be that the positive association 
described also in other studies of increased BMI and anxiety 
could be driven by comorbid depression.
Anxiety Symptomatology, BMI, 
and Testosterone
A well-established fact is that increased BMI is associated with 
higher testosterone levels in women and decreased levels in men 
(28, 46). First, we hypothesized that there might be a mediation 
of the positive association between anxiety and overweight 
(described in several studies) through altered testosterone levels 
associated with increased BMI. If this hypothesis would be true, 
this could change the therapy approach of anxiety disorders 
in obese women, as higher testosterone level might maintain 
TABLE 1 | Logistic regression analysis of anxiety symptomatology and co-factors in women. Anxiety symptomatology (assessed as 0–1, cut-off GAD-7 ≥ 10 points) 
was set as dependent variable. Independent variables were total testosterone, estradiol, and BMI. Stepwise model was used for all analyses. Abbreviations: BMI, body 
mass index; ∆R2, R square change; OR, odds ratio; CI, confidence intervals; n, number of analyzed individuals; p value, significant if <0.05.
Dependent variable: anxiety symptomatology
Independent variables: total testosterone, estradiol, BMI
Included independent 
variable
∆R2 OR CI (95%) p
Premenopausal women. Model summary: R2 = 0.016, p = 0.033, n = 799 1. Total testosterone 0.016 1.763 1.074–2.895 0.025
Not included: estradiol (p = 0.230), BMI (p = 0.124)
Postmenopausal women. Model summary: n = 1,708 Not included: total testosterone (p = 0.278), estradiol (p = 0.423), BMI (p = 0.628)
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anxiety symptomatology. Therefore, obese women with anxiety 
symptomatology could benefit from androgen receptor blockers 
or weight loss as an additive therapy.
However, we did not find a significant association between 
anxiety symptomatology and BMI in either premenopausal or 
postmenopausal women in our study. There could be several 
explanations of this finding:
a. Hormonal changes associated with gradually increasing BMI 
are slow, so a certain “adaptation mechanism” might develop 
and could explain why the BMI-associated sex hormone 
alterations were not proven to play a significant role in anxiety 
pathogenesis in overweight individuals.
b. Hormonal changes associated with obesity might be 
“protective” against anxiety. Therefore, we have looked 
at the concentrations of other sex hormones. Estradiol 
levels were significantly lower in obese premenopausal 
women compared with the normal-weight group, and 
non-significantly (p = 0.086) higher in the group of 
women expressing anxiety symptomatology than in the 
women without anxiety symptomatology. Therefore, lower 
estradiol levels associated with obesity could be protective 
against anxiety in premenopausal women. To support 
our hypothesis, we calculated total and free testosterone 
* estradiol index, as higher levels of both hormones 
were associated with anxiety. Higher values of this index 
(using both total and free testosterone) were significantly 
associated with anxiety symptomatology in premenopausal 
women, but there were no significant differences between 
obese and normal-weight groups.
c. The association between increased testosterone levels and 
anxiety symptomatology independent of BMI might indicate 
that other conditions related to higher testosterone level in 
women [e.g., stress (47), smoking (48), polycystic ovarian 
syndrome (37), insulin resistance (49), and hypothyreosis] 
could be involved in the pathomechanism of anxiety in 
premenopausal women, and most of these conditions are 
highly influenceable by lifestyle changes.
d. Another speculation could be that anxiety per se might lead 
to increased testosterone levels in women, so this might 
be secondary to anxiety. Further studies are required to 
establish causal relationships and to elucidate possible 
neural and molecular mechanism underlying testosterone’s 
actions in anxiety.
In postmenopausal women, no association between testosterone 
and anxiety, as well as anxiety and BMI, was shown in our study. 
Several other factors (e.g., partnership or being married and 
socioeconomic status) might play a more significant role in the 
mechanism of anxiety besides those two factors.
Strengths and Limitations of the Study
To our best knowledge, this is the first study investigating 
associations between anxiety, BMI, and sex hormones in women 
together. It is based on a large cohort of more than 3,000 individuals, 
where strict exclusion criteria were employed. A further strength is 
that anthropometric measurements were taken by study personnel 
rather than self-report, which is related to higher reliability. As a 
limitation, the cross-sectional nature of the study with a relatively 
healthy population sample might have hampered the study of these 
associations. The studied associations might be more pronounced 
in a sample of patients with clinical diagnosis of anxiety disorder. 
Further limitation could be the fact that the sex hormone levels 
were not measured in the same phase of the menstruation cycle. 
However, our aim was not to study association of the anxiety 
symptomatology with the menstruation cycle but to study the 
presence of anxiety symptomatology with levels of sex hormones, 
which was performed on the same day. Another limitation could 
be the polycystic ovary syndrome. However, in our cohort, we did 
not have any female participants labeled with polycystic ovary 
syndrome that was associated with anxiety in several studies (37).
CONCLUSIONS
Although both obesity and anxiety symptomatology in 
premenopausal women were separately associated with the same 
hormonal phenotype – higher testosterone levels – there was an 
opposite impact of anxiety and obesity on estradiol levels. This 
could be the explanation why we did not find a relationship 
between anxiety symptomatology and obesity. This suggests that 
there is no direct link between anxiety, BM, and sex hormones 
and that sex hormone alterations in obese women do not play 
a significant role in developing or maintaining anxiety. As the 
prevalence of obesity and mental disorders is increasing, further 
studies investigating other factors associated with anxiety might 
bring light into the pathomechanism of anxiety in young women. 
In postmenopausal women, other mechanisms seem to work 
than in the premenopausal group.
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